Physiologically based mechanistic modelling to predict complex drug–drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut—The effect of diltiazem on the time-course of exposure to triazolam
- 18 March 2010
- journal article
- Published by Elsevier BV in European Journal of Pharmaceutical Sciences
- Vol. 39 (5), 298-309
- https://doi.org/10.1016/j.ejps.2009.12.002
Abstract
No abstract availableThis publication has 52 references indexed in Scilit:
- Semiphysiologically Based Pharmacokinetic Models for the Inhibition of Midazolam Clearance by Diltiazem and Its Major MetaboliteDrug Metabolism and Disposition, 2009
- Sequential Metabolism Is Responsible for Diltiazem-Induced Time-Dependent Loss of CYP3ADrug Metabolism and Disposition, 2007
- UTILITY OF RECOMBINANT ENZYME KINETICS IN PREDICTION OF HUMAN CLEARANCE: IMPACT OF VARIABILITY, CYP3A5, AND CYP2C19 ON CYP3A4 PROBE SUBSTRATESDrug Metabolism and Disposition, 2004
- PREDICTION OF THE IN VIVO INTERACTION BETWEEN MIDAZOLAM AND MACROLIDES BASED ON IN VITRO STUDIES USING HUMAN LIVER MICROSOMESDrug Metabolism and Disposition, 2003
- Pharmacokinetic analysis of felodipine–grapefruit juice interaction based on an irreversible enzyme inhibition modelBritish Journal of Clinical Pharmacology, 2000
- Population pharmacokinetics of methadone in opiate users: characterization of time‐dependent changesBritish Journal of Clinical Pharmacology, 1999
- Coadministration of Nefazodone and BenzodiazepinesJournal of Clinical Psychopharmacology, 1995
- Pharmacokinetics of Diltiazem and Its Metabolites After Single and Multiple Dosing in Healthy VolunteersTherapeutic Drug Monitoring, 1989
- Pharmacokinetics and absolute bioavailability of diltiazem in humansJournal of Molecular Medicine, 1984
- Pharmacokinetics of diltiazem after intravenous and oral administrationEuropean Journal of Clinical Pharmacology, 1983